Stocktoria

LENZ Therapeutics, Inc. LENZ

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-06-25

LENZ Therapeutics, Inc. statistics & valuation

Market cap$182.5M
P / S9.6×
P / B0.6×
Net margin-430.3%
Return on equity-28.9%
FCF margin-366.7%
Return on capital-32%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-430.30% 202020212022202320242025
Gross margin (%)
202020212022202320242025
Operating margin (%)
-477.50% 202020212022202320242025
Return on equity (%)
-18.40% -24.40% -28.90% 202020212022202320242025
Shares outstanding
10.3M 58.0M 58.2M 2.0M 27.5M 31.3M 202020212022202320242025
Net debt ($)
202020212022202320242025
Share buybacks ($)
202020212022202320242025
Return on assets (%)
-303.00% -17.60% -31.40% -99.40% -23.10% -26.80% 202020212022202320242025
Free cash flow margin (%)
-366.70% 202020212022202320242025
Debt / equity (×)
202020212022202320242025
EPS ($)
-$2.45 -$1.84 -$35.71 -$2.34 -$2.85 202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020
Operating margin-477.5%—————
Net margin-430.3%—————
FCF margin-366.7%—————
Return on assets-26.8%-23.1%-99.4%-31.4%-17.6%-303.0%
Return on equity-28.9%-24.4%75.5%418.1%-18.4%104.5%
Current ratio14.2320.363.6321.1131.440.66

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.